背景:光疗角膜切除术(PTK)已越来越多地用于治疗对其他治疗无反应的严重复发性角膜糜烂综合征(RCES)患者。然而,由于比率不同,目前每项研究的疗效和并发症尚不确定.
目的:本研究的目的是探讨光疗角膜切除术治疗复发性角膜糜烂的安全性和有效性。
方法:本文对Cochrane进行了系统的文献研究,Embase,PubMed,Scopus,和WebofScience有关PTK治疗RCES的文献,直到2022年12月20日。提取的数据包括复发率和不良事件发生率用于荟萃分析。
结果:复发率为18%(95%CI,13%-24%)(129/700眼)。亚组分析显示,损伤后RCE复发率为17%(95%CI,9%-24%),角膜营养不良组为22%(95%CI,11%-32%)。治疗相关的不良事件包括上皮下霾,远视移位,最佳眼镜矫正视力(BSCVA)下降。在这项研究中,这些事件的发生率为13%(95%CI,6%-21%),20%(95%CI,11%-28%),和11%(95%CI,5%-16%),分别。
结论:PTK是复发性角膜糜烂患者的一种有价值的治疗选择,尤其是那些有外伤的人,副作用很小。
BACKGROUND: Phototherapeutic keratectomy (PTK) has been increasingly used to treat severe recurrent corneal erosion syndrome (RCES) patients who do not respond to other treatments. However, the efficacy and complication of each study are currently uncertain due to varying rates.
OBJECTIVE: The objective of this study was to investigate the safety and efficacy of the PTK for recurrent corneal erosions.
METHODS: This article performed a systematic literature research in Cochrane, Embase, PubMed, Scopus, and the Web of Science for the literature on PTK treatment of RCES until December 20, 2022. The extracted data including recurrence rate and the adverse event rate were used for meta-analysis.
RESULTS: The recurrence rate was 18% (95% CI, 13%-24%) (129/700 eyes). Subgroup analysis showed that the RCE recurrence was 17% (95% CI, 9%-24%) after trauma and 22% (95% CI, 11%-32%) in the corneal dystrophy group. Treatment-related adverse events included subepithelial haze, hyperopic shift, and decrease of the best spectacle-corrected visual acuity. In this study, the incidence of these events was 13% (95% CI, 6%-21%), 20% (95% CI, 11%-28%), and 11% (95% CI, 5%-16%), respectively.
CONCLUSIONS: PTK represented a valuable treatment option for patients with recurrent corneal erosions, especially those with traumatic injuries, which had minimal side effects.